Company Overview and News
Mumbai : Benchmark BSE Sensex on Monday suffered its worst single-day loss in seven months, extending its fall for a fifth day due to a meltdown in banking and auto stocks on liquidity concerns and a rout in global markets.
BAJAJ-AUTO MUTHOOTFIN 532977 533398 BHRQY 533278 511288 535789 500470 532187 HDFCBANK HEROMOTOCO LHFLY 500570 BHARTIARTL TATAMOTORS CLNDY 500253 GICHSGFIN GRUH YESBANK EDELWEISS INDUSINDBK IBN IDKQY CANFINHOME 532648 535322 GRHFY YYBKY 511196 532922 511676 REPCOHOME IBULHSGFIN 532454 500182 ICICIBANK TTST TATASTEEL TATLY LICHSGFIN HDB 532174 500180 HRTQY COALINDIA TTM
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
The Indian stock market has turned negative this Wednesday with the Nifty50 down 50 points and is trading at 11,228 while the Sensex is trading lower by 185 points at 37,104.
UBNC MUTHOOTFIN MONSANTO GESHIP HFCL 533398 500183 500470 TTST TATASTEEL TATLY 524084 500620 DCMSHRIRAM 523367
The Indian stock market has turned negative this Wednesday afternoon with the Nifty50 down 28 points and is trading at 11,250 while the Sensex is trading lower by 82 points at 37,207.
MUTHOOTFIN 500325 532712 532832 533137 DEN RCOM SONATSOFTW 500179 GAILF BEL CLNDY RLNIY SBAZ BHQRY RELCAPITAL 532508 JETAIRWAYS JSWSTEEL 500182 TATASTEEL TATLY GAILY GLOBUSSPR COALINDIA IBREALEST 523367 533150 500228 RELIANCE 532617 533273 533398 533278 HCL-INSYS 532221 500470 RIGD HEROMOTOCO JSL 500111 UBNC 533104 OBZIY GODREJPROP TTST OBEROIRLTY DCMSHRIRAM HRTQY 500049
The Indian benchmark indices continues to trade on a positive note this Wednesday afternoon with the Nifty50 up 21 points and is trading at 11,300 while the Sensex is trading higher by 53 points at 37,343.
HINDCOPPER KOHINOOR MUTHOOTFIN PGEL 500325 500228 RELIANCE 532617 HNDZY HFCL 533398 NAUKRI 532777 533137 HCL-INSYS DEN 532221 500470 SONATSOFTW RIGD 500179 JSL GAILF BEL RLNIY SBAZ BHQRY HINDALCO 532508 533581 513599 JETAIRWAYS JSWSTEEL 533104 512559 HNDNF 500183 TTST TATASTEEL TATLY GAILY DCMSHRIRAM 500049 GLOBUSSPR 500440 500188 HINDZINC 523367
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty50 trading at 11,509, up 32 points while the Sensex is trading higher by 128 points at 38,147.
523768 MUTHOOTFIN DVSLY 500325 532839 NDL PRMQY ICLQY 532832 511218 532400 KPIT DISHTV 532641 USHAMART 532482 534816 UCLQY SRRQY GAILF MS BEL CLNDY SUNTV RLNIY GICHSGFIN BHQRY 524804 UHBTY YYBKY 511676 532822 ULTRACEMCO TATASTEEL TATLY GAILY KOTAKBANK 500302 COALINDIA IBREALEST 517146 BHRYY AUROPHARMA GUJBOROS 539254 RELIANCE 533273 532538 533398 SRTRANSFIN 532733 533278 GRANULES 500470 RIGD INFRATEL ZEEL ADANITRANS 516022 YESBANK INDIGO KMBKY UCLQF 532648 PEL 539448 STARPAPER OBZIY TTST OBEROIRLTY ZEEEY ARBQY 505537 IDEA 500247 500049 SNQVY
Muthoot Finance (MFIN) Wednesday registered a rise of 43 percent in its consolidated net profit at Rs 492 crore in first quarter ended June of the current fiscal. The company had recorded a net profit of Rs 345 crore in the same quarter of 2017-18.
MUTHOOTFIN AAF 533398
The Indian market extended the morning losses in the afternoon with the Nifty50 trading at 11,455, down 65 points and the Sensex trading 210 points lower at 37,947.
MUTHOOTFIN RELEY CREST RIFS RELFF 517506 533398 500390 RELINFRA 532234 TTKPRESTIG 511413 RIFA NATIONALUM
The Indian market has extended the morning loses this Wednesday afternoon with the Nifty50 trading at 11,422, down 97 points while the Sensex is trading lower by 292 points at 37,865.
ESL SUZLON MUTHOOTFIN BRIGADE TCHQY ICLQY 532755 SYNDIBANK 532483 534816 NSZTY BEL SUEL SUNTV BHQRY NESTLEIND YYBKY 532822 532667 CNRYY TECHM CASTROLIND 532276 SICAL CANBK ANDHRABANK BHRYY 533150 533273 532418 533398 TATACOMM 532733 CSLQY ENGINERSIN 520086 INFRATEL 500790 503100 500870 YESBANK UBNC HINDALCO 532929 PHOENIXLTD 533264 532648 HNDNF 532178 OBZIY GODREJPROP OBEROIRLTY IDEA 500049 SNQVY 500483 500440
The Indian benchmark indices have turned negative this Wednesday afternoon with the Nifty50 trading at 11,452, down 67 points while the Sensex is trading lower by 205 points at 37,952.
ESL SUZLON MUTHOOTFIN 500325 BRIGADE TCHQY 532514 532755 JSWENERGY 535789 SYNDIBANK IGL 532483 534816 500570 BEL SUEL CLNDY SUNTV RLNIY BHQRY 532667 CNRYY TECHM CASTROLIND 532276 TATASTEEL TATLY SICAL CANBK COALINDIA ANDHRABANK BHRYY 532939 533150 RELIANCE 533273 532418 533398 TATACOMM 533278 532733 CSLQY 500470 ENGINERSIN RIGD 520086 INFRATEL TATAMOTORS 500870 RPOWER 517354 HVLQY 532929 IDKQY 533264 533148 IBULHSGFIN 532178 OBZIY GODREJPROP TTST OBEROIRLTY HAVELLS 500049 SNQVY 500483 TTM
The Indian benchmark indices are trading on a flat to positive note this Wednesday morning with the Nifty50 trading at 11,521, up 1 point while the Sensex is trading higher by 38 points at 38,196.
ESL SUZLON MUTHOOTFIN 500325 AUROPHARMA RELIANCE 533398 TATACOMM 532733 CADILAHC CSLQY 532321 532221 SONATSOFTW RIGD AJANTPHARM 520086 GAILF BEL SUEL SUNTV RLNIY 500870 BHQRY 524804 533264 532667 CDLYY CASTROLIND 532331 ARBQY GAILY SICAL SNQVY 500049 500483
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...